Deciphering cell signaling rewiring in human disorders

The knowledge of cell molecular mechanisms implicated in human diseases is expanding and should be converted into guidelines for deciphering pathological cell signaling and suggesting appropriate treatment. The basic assumption is that during a pathological transformation, the cell does not create new signaling mechanisms, but rather it hijacks the existing molecular programs. This affects not only intracellular functions, but also a crosstalk between different cell types resulting in a new, yet pathological status of the system. There is a certain combination of molecular characteristics dictating specific cell signaling states that sustains the pathological disease status. Identifying and manipulating the key molecular players controlling these cell signaling states, and shifting the pathological status toward the desired healthy phenotype, are the major challenge for molecular biology of human diseases.

💡 Research Summary

The paper proposes a unifying framework for understanding how human diseases remodel existing cellular signaling networks rather than inventing entirely new pathways. The authors argue that during pathological transformation a cell hijacks pre‑existing molecular programs, rearranging them into a disease‑specific combination of intracellular cascades and inter‑cellular communication loops. This “signaling rewiring” creates a distinct pathological state that is sustained by a defined set of molecular characteristics. To dissect this state, the authors advocate a systems‑biology pipeline: large‑scale transcriptomic, proteomic and metabolomic datasets are integrated, network‑based module detection and Bayesian inference are applied, and machine‑learning algorithms extract disease‑specific “signaling signatures.” These signatures highlight core hub molecules—key transcription factors (e.g., STAT3, NFAT), kinases (AKT, CDK), receptors (TLR4, PD‑1) and regulatory RNAs—that act as the pivotal nodes of rewiring. Once identified, the hubs can be modulated through CRISPR‑based gene editing, small‑molecule inhibitors, PROTAC degraders, monoclonal antibodies, or combinatorial immunomodulators. Crucially, the strategy emphasizes precise adjustment of the transition nodes rather than blanket blockade of entire pathways, thereby preserving normal cellular functions and reducing adverse effects. The authors further suggest that multi‑hub “signal reset” therapies, tailored to individual omics profiles, could outperform conventional single‑target drugs, especially in complex diseases such as cancer, autoimmune disorders, and neurodegeneration where tumor‑stroma, immune‑cell, and neuronal cross‑talk continuously reshape the signaling landscape. In summary, the work reframes disease biology as a problem of signal‑network re‑allocation, provides a methodological roadmap for hub identification, and outlines therapeutic avenues for shifting pathological signaling back toward a healthy phenotype.